Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GGT1 | P19440 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1404297 | 1.00 | KDM4E (0.48) | KDM4EHSD17B10HPGDMEN1KMT2A | |
| SCHEMBL13143968 | 0.91 | KDM4E (0.44) | KDM4EHSD17B10HPGDMEN1KMT2A | |
| Salmisteine SCHEMBL1404300 | 0.89 | PTGS2 (0.49) | KDM4EHSD17B10HPGDMEN1KMT2A | |
| Salmisteine SCHEMBL374402 | 0.89 | PTGS2 (0.49) | KDM4EHSD17B10HPGDMEN1KMT2A | |
| SCHEMBL13142915 | 0.89 | KDM4E (0.39) | KDM4EHSD17B10HPGDMEN1KMT2A | |
| SCHEMBL13142908 | 0.86 | KDM4E (0.37) | KDM4EHSD17B10HPGDMEN1KMT2A | |
| SCHEMBL13142990 | 0.85 | KDM4E (0.36) | KDM4EHSD17B10HPGDMEN1KMT2A | |
| SCHEMBL13142940 | 0.85 | KDM4E (0.36) | KDM4EHSD17B10HPGDMEN1KMT2A | |
| SCHEMBL13143028 | 0.85 | KDM4E (0.38) | KDM4EHSD17B10HPGDMEN1KMT2A | |
| SCHEMBL10365310 | 0.85 | PTGS2 (0.45) | KDM4EHSD17B10HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025006-A1 | Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2015-01-22 | — | — | US | claimed |
| EP-2755645-A1 | PHARMACEUTICAL COMBINATIONS INCLUDING ANTI-INFLAMMATORY AND ANTIOXIDANT CONJUGATES USEFUL FOR TREATING METABOLIC DISORDERS | Genmedica Therapeutics SL (ES) | 2014-07-23 | — | — | EP | claimed |
| WO-2013037985-A1 | PHARMACEUTICAL COMBINATIONS INCLUDING ANTI-INFLAMMATORY AND ANTIOXIDANT CONJUGATES USEFUL FOR TREATING METABOLIC DISORDERS | GENMEDICA THERAPUTICS SL (ES) | 2013-03-21 | — | — | WO | claimed |
| US-20150025006-A1 | Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2015-01-22 | — | — | US | disclosed |
| EP-2755645-A1 | PHARMACEUTICAL COMBINATIONS INCLUDING ANTI-INFLAMMATORY AND ANTIOXIDANT CONJUGATES USEFUL FOR TREATING METABOLIC DISORDERS | Genmedica Therapeutics SL (ES) | 2014-07-23 | — | — | EP | disclosed |
| US-8575217-B2 | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders | GENMEDICA THERAPEUTICS SL (ES) | 2013-11-05 | — | — | US | disclosed |
| US-20130281413-A1 | Salicylate Conjugates Useful For Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2013-10-24 | — | — | US | disclosed |
| US-20130281520-A1 | Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2013-10-24 | — | — | US | disclosed |
| WO-2013037985-A1 | PHARMACEUTICAL COMBINATIONS INCLUDING ANTI-INFLAMMATORY AND ANTIOXIDANT CONJUGATES USEFUL FOR TREATING METABOLIC DISORDERS | GENMEDICA THERAPUTICS SL (ES) | 2013-03-21 | — | — | WO | disclosed |
| EP-2291182-A1 | SALICYLATE CONJUGATES USEFUL FOR TREATING METABOLIC DISORDERS | Genmedica Therapeutics SL (ES) | 2011-03-09 | — | — | EP | disclosed |
| US-20100234452-A1 | Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2010-09-16 | — | — | US | disclosed |
| US-20090298923-A1 | Salicylate Conjugates Useful for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2009-12-03 | — | — | US | disclosed |
| WO-2009138437-A1 | SALICYLATE CONJUGATES USEFUL FOR TREATING METABOLIC DISORDERS | GENMEDICA THERAPEUTICS SL (ES) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281520-A1 | Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders | HSD17B14, SORD, GPX4 | KDM4E 3003/4885HSD17B10 73/4885HPGD 45/4885 |
| US-20100234452-A1 | Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | HSD17B14, SORD, GPX4 | KDM4E 3003/4885HSD17B10 73/4885HPGD 45/4885 |
| US-20090298923-A1 | Salicylate Conjugates Useful for Treating Metabolic Disorders | HSD17B14, FAH, SORD | KDM4E 2985/4885HSD17B10 28/4885HPGD 55/4885 |
| US-20130281413-A1 | Salicylate Conjugates Useful For Treating Metabolic Disorders | HSD17B14, FAH, SORD | KDM4E 2985/4885HSD17B10 28/4885HPGD 55/4885 |
| US-20150025006-A1 | Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | IAPP, AMY2A, GPR119 | KDM4E 4229/4885HSD17B10 487/4885HPGD 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.